Related references
Note: Only part of the references are listed.Management of febrile neutropaenia: ESMO Clinical Practice Guidelines
J. Klastersky et al.
ANNALS OF ONCOLOGY (2016)
The prevention and management of infections due to multidrug resistant organisms in haematology patients
Jason A. Trubiano et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey
E. M. Trecarichi et al.
CLINICAL MICROBIOLOGY AND INFECTION (2015)
Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review
Xiao Jun Wang et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Prediction of Serious Complications in Patients With Seemingly Stable Febrile Neutropenia: Validation of the Clinical Index of Stable Febrile Neutropenia in a Prospective Cohort of Patients From the FINITE Study
Alberto Carmona-Bayonas et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
Thomas J. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Value of lipopolysaccharide binding protein as diagnostic marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin, and interleukin 6
Luis Garcia de Guadiana-Romualdo et al.
SUPPORTIVE CARE IN CANCER (2015)
The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials
Li Wang et al.
SUPPORTIVE CARE IN CANCER (2015)
Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis
Chun-Wei Wu et al.
SUPPORTIVE CARE IN CANCER (2015)
Time to antibiotics and outcomes in cancer patients with febrile neutropenia
Thomas Perron et al.
BMC HEALTH SERVICES RESEARCH (2014)
The Global Challenge of Carbapenem-Resistant Enterobacteriaceae in Transplant Recipients and Patients With Hematologic Malignancies
Michael J. Satlin et al.
CLINICAL INFECTIOUS DISEASES (2014)
Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review
Gary H. Lyman et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Antibiotic resistance in cancer patients
Carlota Gudiol et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2014)
Colony-stimulating factors for chemotherapy-induced febrile neutropenia
Rahul Mhaskar et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance
E. Montassier et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2013)
Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome
Barbara Deschler et al.
HAEMATOLOGICA (2013)
Cost Effectiveness of Primary Pegfilgrastim Prophylaxis in Patients With Breast Cancer at Risk of Febrile Neutropenia
Maureen J. Aarts et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline
Christopher R. Flowers et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis Against Febrile Neutropenia in Lymphoma Patients
Nina Lathia et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas
Alexandre Chan et al.
SUPPORTIVE CARE IN CANCER (2013)
Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia
Shin Ahn et al.
SUPPORTIVE CARE IN CANCER (2013)
The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients
Jean Klastersky et al.
SUPPORTIVE CARE IN CANCER (2013)
US FDA patient-reported outcome guidance: great expectations and unintended consequences
Sheri Fehnel et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2013)
A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia
Brian Dulisse et al.
JOURNAL OF MEDICAL ECONOMICS (2013)
Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia
Mical Paul et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
Characteristics and Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections in Patients with Cancer Treated with Vancomycin: 9-Year Experience at a Comprehensive Cancer Center
Sminil N. Mahajan et al.
ONCOLOGIST (2012)
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
Katy L. Cooper et al.
BMC CANCER (2011)
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
Alison G. Freifeld et al.
CLINICAL INFECTIOUS DISEASES (2011)
Strategies for Reduction in Duration of Antibiotic Use in Hospitalized Patients
Yoshiro Hayashi et al.
CLINICAL INFECTIOUS DISEASES (2011)
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
M. S. Aapro et al.
EUROPEAN JOURNAL OF CANCER (2011)
Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy
Young Eun Ha et al.
SUPPORTIVE CARE IN CANCER (2011)
Cost-Effectiveness of Granulocyte Colony-Stimulating Factor Prophylaxis for Febrile Neutropenia in Breast Cancer in the United Kingdom
Sophie Whyte et al.
VALUE IN HEALTH (2011)
Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial
Lila Bouadma et al.
LANCET (2010)
Effect of Procalcitonin-Based Guidelines vs Standard Guidelines on Antibiotic Use in Lower Respiratory Tract Infections The ProHOSP Randomized Controlled Trial
Philipp Schuetz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy
Ulrich Gatzemeier et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy
A. Engert et al.
LEUKEMIA & LYMPHOMA (2009)
Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin's Lymphoma
Andreas Engert et al.
ONKOLOGIE (2009)
Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial
Marcel Hochreiter et al.
CRITICAL CARE (2009)
Use of procalcitonin to shorten antibiotic treatment duration in septic patients - A randomized trial
Vandack Nobre et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy
A. del Giglio et al.
BMC CANCER (2008)
Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients
Luciano de Souza Viana et al.
SUPPORTIVE CARE IN CANCER (2008)
Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N)
Lynne I. Wagner et al.
SUPPORTIVE CARE IN CANCER (2008)
Prediction of outcome in cancer patients with febrile neutropenia:: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1β, -6, -8 and -10
A. Uys et al.
EUROPEAN JOURNAL OF CANCER CARE (2007)
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review
Nicole M. Kuderer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Economic burden of haematological adverse effects in cancer patients - A systematic review
S. Y. Liou et al.
CLINICAL DRUG INVESTIGATION (2007)
Antibiotic prophylaxis in neutropenic patients - New evidence, practical decisions
Leonard Leibovici et al.
CANCER (2006)
Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications
Jean Klastersky et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Descriptive and prognostic value of patient-reported outcomes: The bortezomib experience in relapsed and refractory multiple myeloma
D Dubois et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies
S Reuter et al.
CLINICAL INFECTIOUS DISEASES (2005)
Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia
L Persson et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Fluoroquinolone resistance of Escherichia coli at a cancer center:: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia
WV Kern et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2005)
Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections:: cluster-randomised, single-blinded intervention trial
M Christ-Crain et al.
LANCET (2004)
Economic evaluations of granulocyte colony-stimulating factor - In the prevention and treatment of chemotherapy-induced neutropenia
M Esser et al.
PHARMACOECONOMICS (2003)
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
WT Hughes et al.
CLINICAL INFECTIOUS DISEASES (2002)
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients
J Klastersky et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
